Following approval from the National Institute for Health and Care Excellence people with an aggressive form of blood cancer can now be offered Glofitamab (Columvi®). This will be offered to around 300 people a year with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) — a form of non-Hodgkin lymphoma which has returned or not responded to chemotherapy. More….
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.
Create a network to share documents, knowledge and best practice with your colleagues. Set up a network to keep in touch with other people in your organisation or with shared interest groups across organisational boundaries.
Networks can be open to all or available only to a closed group defined by the administrator.
Join or create a network here.
